Table 3.
Summary of some ongoing clinical trials in NEPC.
| S. No. | Name of the Drug | Target | Trial No. | References |
|---|---|---|---|---|
| 1. | Alisertib (MLN8237) | AURKA | Phase II completed (NCT01799278) |
[79] |
| 2. | Intravenous copper and oral disulfiram | Nuclear Protein Localization Protein 4 (NPL4) | Phase Ib (NCT02963051) |
[198,200] |
| 3. | Rovalpituzumab-tesirine (SC16LD6.5) | DLL3 | Phase I & II completed (NCT02709889) |
[114] |
| 4. | Avelumab | PD-L1 | Phase II (NCT03179410) |
[201] |
| 5. | GSK126, GSK343, fGSK503 | EZH2 | Preclinical | [85] |
| 6. | 177Lu-PSMA-617 | PSMA | Phase III (NCT03511664) |
[202,203,204] |
| 7. | Next-generation AR/pathway inhibitors (Orteronel + Prednisone) | CYP17 lyase | Phase II Completed (NCT01549951) |
[205,206] |
| 8. | Seviteronel | CYP17 lyase and AR inhibitor | Phase II (NCT02445976) |
[207] |
| 9. | Panobinostat and Bicalutamide | histone deacetylase inhibitor (epigetic pathways) | Phase I & II (NCT00878436) |
[208,209] |
| 10. | Cabazitaxel + Carboplatin + Prednisone + Olaparib | DNA recombination | Phase II (NCT03263650) |
[210] |
| 11. | Radium-223 + Dexamethasone | mCRPC with bone metastasis | Phase IV (NCT03432949) |
[211] |